{"url_path":"/sec/apus/8-k/2026-07-13/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-13","source_url":"https://www.sec.gov/Archives/edgar/data/1894525/0001213900-26-077591-index.html","accession_number":"0001213900-26-077591","cik":"0001894525","ticker":"APUS","issuer_name":"Apimeds Pharmaceuticals US, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1894525/0001213900-26-077591-index.html","primary_entity_key":"0001894525","primary_entity_name":"Apimeds Pharmaceuticals US, Inc."},"word_count":455,"has_tables":true,"body_markdown":"**Item 8.01. Other Events.**\n\n** **\n\nOn December 1, 2025, Apimeds Pharmaceuticals US,\nInc., a Delaware corporation (the “**Company**”), obtained approval of its stockholders holding a majority of the voting\npower of the Company’s outstanding capital stock, by written consent (the “**Written Consent**”), to effect a reverse\nstock split of its issued and outstanding shares of common stock at a ratio of one-for-ten (1-for-10) (the “**Reverse Stock Split**”)\nand to amend the Company’s Amended and Restated Certificate of Incorporation (the “**Charter Amendment**”) accordingly.\n\n \n\nIn connection with the Written Consent, the Company\nfiled and mailed an information statement (the “**Information Statement**”) to its stockholders pursuant to Rule 14c-2\nunder the Securities Exchange Act of 1943, as amended. The Reverse Stock Split will not become effective until at least 20 calendar days\nafter the mailing of the definitive Information Statement (the “**Waiting Period**”).\n\n \n\nAs previously disclosed in the Company’s\nCurrent Report on Form 8-K filed with the Securities and Exchange Commission on March 16, 2026, the Company had expected to file the Charter\nAmendment with the Secretary of State of the State of Delaware to effect the Reverse Stock Split on or about March 25, 2026, with the\nReverse Stock Split becoming effective on March 26, 2026. The Company did not file the Charter Amendment on that date. The Waiting Period\nhas now passed, and the Company expects to file the Charter Amendment with the Secretary of State of the State of Delaware to effect the\nReverse Stock Split on or about July 23, 2026.\n\n \n\nThe Company has determined that the Reverse Stock\nSplit will become effective as of 12:01 a.m. Eastern Time on July 24, 2026 (the “**Effective Date**”), in lieu of the previously\nannounced Effective Date of March 26, 2026. The Company expects that its common stock will begin trading on a split-adjusted basis on\nthe NYSE American LLC under the symbol “APUS”, at the open of trading on July 24, 2026. The new CUSIP number for the Company’s\ncommon stock following the Reverse Stock Split will be 03771D201.\n\n** **\n\nUpon effectiveness of the Reverse Stock Split,\nevery ten (10) shares of the Company’s issued and outstanding common stock will automatically be combined and changed into one (1)\nshare of the Company’s issued and outstanding common stock.\n\n \n\nThe information set forth\nin this Item 8.01 does not purport to be complete and is qualified in its entirety by reference to the disclosure under the heading “The\nReverse Stock Split” in the Information Statement, which was dated February 26, 2026, and first mailed to stockholders on March\n5, 2026, and is incorporated herein by reference. \n\n \n\nThe Company will announce\nthe effectiveness of the Reverse Stock Split in a subsequent Current Report on Form 8-K once the Effective Date occurs."}